Published Online:7 May 2013https://doi.org/10.4155/tde.13.24
Abstract
Background: The objective of this work was to study transdermal delivery of methotrexate using silicon microneedles and simulate plasma concentrations using a population pharmacokinetic model. Results: Characterization of silicon microneedles was carried out by scanning electron microscopy, transepidermal water loss, methylene blue staining, calcein imaging, pore permeability index and confocal microscopy, which confirmed the formation of microchannels. In vitro permeation studies were performed to study the enhancement in transdermal delivery following microporation. Conclusion: Simulation data demonstrated that with 16, 64, 128 and 192 microneedles, mean plasma concentrations of 0.3, 1.4, 2.8 and 4.2 ng/ml, respectively, can be achieved. Thus, therapeutically relevant doses could be delivered in pediatrics by increasing the number of microneedles and patch area.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Nunn T, Williams J. Formulation of medicines for children. Br. J. Clin. Pharmacol.59(6),674–676 (2005).▪▪ Highlights the need to develop a suitable delivery system for the pediatric population in order to increase patient compliance.
- 2 Shah UU, Roberts M, Gul M, Tuleu C, Beresford MW. Needle-free and microneedle drug delivery in children: a case for disease-modifying antirheumatic drugs (DMARDs). Int. J. Pharm.416(1),1–11(2011).
- 3 Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol.26(11),1261–1268 (2008).
- 4 Roxhed N, Samel B, Nordquist L, Griss P, Stemme G. Painless drug delivery through microneedle-based transdermal patches featuring active infusion. IEEE Trans. Biomed. Eng.55(3),1063–1071 (2008).
- 5 Chen B, Wei J, Iliescu C. Sonophoretic enhanced microneedles array (SEMA)–Improving the efficiency of transdermal drug delivery. Sens. Actuators B Chem.145(1),54–60 (2010).
- 6 Banga AK. Microporation applications for enhancing drug delivery. Expert Opin. Drug Deliv.6(4),343–354 (2009).▪▪ Expresses the importance of microporation and mechanism of drug delivery by the created microchannels.
- 7 Wilke N, Reed M, Morrissey A. The evolution from convex corner undercut towards microneedle formation: theory and experimental verification. J. Micromech. Microeng.16,808–814 (2006).
- 8 Kalluri H, Kolli CS, Banga AK. Characterization of microchannels created by metal microneedles: formation and closure. AAPS J.13(3),473–481 (2011).▪▪ Reports the formation and closure of microchannels after microporation. This article is important because it is based on a simulation study on the assumption that the pores remain open until 72 h under occluded conditions to predict the plasma concentration for microporated skin.
- 9 Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J. Am. Acad. Dermatol.52(2),316–340 (2005).
- 10 Patino-Garcia A, Zalacain M, Marrodan L, San-Julian M, Sierrasesumaga L. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J. Pediatr.154(5),688–693 (2009).
- 11 Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J. Pharm. Pharmacol.60(1),27–33 (2008).▪ Reports the use of methotrexate for transdermal delivery and its quantification assay.
- 12 Haq MI, Smith E, John DN et al. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed. Microdevices11(1),35–47 (2009).
- 13 Kolli CS, Banga AK. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm. Res.25(1),104–113 (2008).
- 14 Kalluri H, Banga AK. Formation and closure of microchannels in skin following microporation. Pharm. Res.28(1),82–94 (2011).
- 15 Li G, Badkar A, Nema S, Kolli CS, Banga AK. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. Int. J. Pharm.368(1–2),109–115 (2009).
- 16 Colom H, Farre R, Soyet D et al. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma. Ther. Drug Monit.31(1),76–85 (2009).▪ Reports the pharmacokinetic parameters of methotrexate in pediatric patients. These parameters were used for simulating plasma concentration in the pediatric population.
- 17 Donnelly RF, Singh TR, Tunney MM et al. Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm. Res.26(11),2513–2522 (2009).
- 18 Li G, Badkar A, Kalluri H, Banga AK. Microchannels created by sugar and metal microneedles: characterization by microscopy, macromolecular flux and other techniques. J. Pharm. Sci.99(4),1931–1941 (2010).
- 19 Netzlaff F, Kostka KH, Lehr CM, Schaefer UF. TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. Eur. J. Pharm. Biopharm.63(1),44–50 (2006).
- 20 Al-Qallaf B, Das DB. Optimizing microneedle arrays to increase skin permeability for transdermal drug delivery. Ann. NY Acad. Sci.1161,83–94 (2009).
- 21 Enfield J, O’Connell ML, Lawlor K, Jonathan E, O’Mahony C, Leahy M. In vivo dynamic characterization of microneedle skin penetration using optical coherence tomography. J. Biomed. Opt.15(4),046001(2010).
- 22 Kelly A, Ramanan AV. The principles of pharmacological treatment of juvenile idiopathic arthritis. Paediatr. Child Health (Oxford)21(12),563–568 (2011).
- 23 Quartier P. Current treatments for juvenile idiopathic arthritis. Joint Bone Spine77(6),511–516 (2010).
- 24 Kugathasan S, Newman AJ, Dahms BB, Boyle JT. Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving long-term, weekly methotrexate therapy. J. Pediatr.128(1),149–151 (1996).
- 25 Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J. Pediatr.134(1),47–52 (1999).
- 26 Vagace JM, de la Maya MD, Caceres-Marzal C, Murillo S, Gervasini G. Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia/lymphoma. Crit. Rev. Oncol. Hematol.84(2),274–286 (2012).
- 27 Ramanan AV, Campbell-Webster N, Ota S et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum.52(11),3570–3578 (2005).
- 28 Kellie SJ, Wong CK, Pozza LD et al. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a Phase II study in newly diagnosed children. Med. Pediatr. Oncol.39(3),168–174 (2002).
- 101 Truven health analytics. www.micromedex.com (Accessed 10 December 2012)
